GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout ... and RA Capital among its notable investors. Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor ...

Embedding the patient voice into the DNA of a pharmaceutical company ... VP and country medical director, UK and Ireland at GSK, which has a dedicated Patients in Partnership team working to ...

GSK's severe ... at a future medical congress, but is strong enough to warrant discussions with regulators about extending the indications for Nucala, according to the pharma group.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

India's GlaxoSmithKline Pharmaceuticals ... deals with Pfizer worth a combined $897 million to manufacture products for the U.S. pharmaceutical giant. Samsung Biologics unveils $897 million ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products.” GSK is due ...